Chris Markoch shares 3 high free cash flow stocks for investors who want to sleep better!!
3 extracted signals · 3 resolved · 0 still active
MarketBeatIndependent analyst profile- Source published
- 17 Nov 2025, 04:34 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The fundamental analysis focuses on free cash flow yield as a key metric, identifying stocks growing their balance sheet and provides investor security. The analyst identifies three specific stocks: Salesforce, Applied Materials, and Gilead Sciences, and mentions the price predictions for each one. Salesforce, with ticker CRM, has a 5.06% free cash flow yield, most of its ten billion revenue coming from recurring revenue and has a price forecast of $325.23. Applied Materials, with ticker AMAT, has a 3.07% free cash flow yield and is positioned to benefit from growth in AI and data centers with 1.4 billion in buybacks with a high estimate up to 300 and an average target price for 2025 of $226.09. The third stock, Gilead Sciences, with ticker GILD, and a 6.19% free cash flow, and a forecast average target price of $129.13, and has existing proven drug portfolio used to treat HIV and Hepatitis C. No risk analysis is provided.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
MarketBeat
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.